References
- McClungMRLewieckiEMCohenSBAMG 162 Bone Loss Study GroupDenosumab in postmenopausal women with low bone mineral densityN Engl J Med2006354882183116495394
- BoneHGWagmanRBBrandiML10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionLancet Diabetes Endocrinol2017551352328546097
- KamimuraMNakamuraYIkegamiSUchiyamaSKatoHTaguchiASignificant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patientsOsteoporos Int201728555956627650642
- TsaiJNUihleinAVLeeHTeriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trialLancet20133829886505623683600
- NakamuraYSuzukiTKamimuraMTwo-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic womenBone Res201751605528690911
- LederBZTsaiJNJiangLALeeHImportance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the Denosumab and Teriparatide Follow-up Study (DATA-Follow-up)Bone201798545828286299
- NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
- ArlotMMeunierPJBoivinGDifferential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parametersJ Bone Miner Res20052071244125315940379
- Fahrleitner-PammerABurrDDobnigHImprovement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatmentBone201689162427185100
- YagiMOhneHKonomiTTeriparatide improves volumetric bone mineral density and fine bone structure in the UIV+1 vertebra, and reduces bone failure type PJK after surgery for adult spinal deformityOsteoporos Int201627123495350227341809
- OrimoHNakamuraTHosoiTJapanese 2011 guidelines for prevention and treatment of osteoporosis – executive summaryArch Osteoporos2012732023203733
- IkegamiSKamimuraMUchiyamaSNakamuraYMukaiyamaKKatoHClinical implications of hip flexion in the measurement of spinal bone mineral densityJ Clin Densitom20161927027626778480
- EastellRO’NeillTWHofbauerLCPostmenopausal osteoporosisNat Rev Dis Primers201621606927681935
- ShigdelROsimaMAhmedLABone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fracturesBone2015811626112819
- AhmedLAShigdelRJoakimsenRMMeasurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fracturesOsteoporos Int20152682137214625876879
- ZebazeRTakao-KawabataRPengYIncreased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatideBone201799808428323145
- KamimuraMNakamuraYIkegamiSUchiyamaSKatoHBisphosphonate Pre-Treatment Diminishes the Therapeutic Benefits of Teriparatide in Japanese Osteoporotic PatientsTohoku J Exp Med2016239172427150954
- MinneHAudranMSimõesMEEUROFORS Study GroupBone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS studyCurr Med Res Opin200824113117312818838053
- NakamuraYSuzukiTKamimuraMIkegamiSUchiyamaSKatoHAlfacalcidol increases the therapeutic efficacy of ibandronate on bone mineral density in Japanese women with primary osteoporosisTohoku J Exp Med2017241431932628458336
- EriksenEFKeavenyTMGallagherERKregeJHLiterature review: the effects of teriparatide therapy at the hip in patients with osteoporosisBone20146724625625053463